Next Article in Journal
Complexity of Human Cytomegalovirus Infection in South African HIV-Exposed Infants with Pneumonia
Next Article in Special Issue
Characterization of Immune Response Diversity in Rodents Vaccinated with a Vesicular Stomatitis Virus Vectored COVID-19 Vaccine
Previous Article in Journal
Infection with IBV DMV/1639 at a Young Age Leads to Increased Incidence of Cystic Oviduct Formation Associated with False Layer Syndrome
Previous Article in Special Issue
Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 14
Issue 5
10.3390/v14050854
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice

by
Longbo Hu
1,†,
Yuhua Xu
2,†,
Liping Wu
1,
Jin Feng
1,2,3,
Lu Zhang
4,
Yongjie Tang
1,
Xiang Zhao
1,
Runming Mai
2,
Liyun Chen
2,
Lingling Mei
1,
Yuanzhen Tan
2,
Yingying Du
2,
Yanping Zhen
2,
Wenhan Su
2 and
Tao Peng
1,2,*
1
State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China
2
Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China
3
Guangzhou Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, Guangzhou 510005, China
4
Guangzhou Customs District Technology Center, Guangzhou 510665, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Viruses 2022, 14(5), 854; https://doi.org/10.3390/v14050854
Submission received: 1 April 2022 / Revised: 14 April 2022 / Accepted: 18 April 2022 / Published: 21 April 2022
(This article belongs to the Special Issue SARS-CoV-2 and Other Vaccines: Immunogenicity Parameters and Protection)
Browse Figures
Versions Notes

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially emerging variants, poses an increased threat to global public health. The significant reduction in neutralization activity against the variants such as B.1.351 in the serum of convalescent patients and vaccinated people calls for the design of new potent vaccines targeting the emerging variant. However, since most vaccines approved and in clinical trials are based on the sequence of the original SARS-CoV-2 strain, the immunogenicity and protective efficacy of vaccines based on the B.1.351 variant remain largely unknown. In this study, we evaluated the immunogenicity, induced neutralization activity, and protective efficacy of wild-type spike protein nanoparticle (S-2P) and mutant spike protein nanoparticle (S-4M-2P) carrying characteristic mutations of B.1.351 variant in mice. Although there was no significant difference in the induction of spike-specific IgG responses in S-2P- and S-4M-2P-immunized mice, neutralizing antibodies elicited by S-4M-2P exhibited noteworthy, narrower breadth of reactivity with SARS-CoV-2 variants compared with neutralizing antibodies elicited by S-2P. Furthermore, the decrease of induced neutralizing antibody breadth at least partly resulted from the amino acid substitution at position 484. Moreover, S-4M-2P vaccination conferred insufficient protection against live SARS-CoV-2 virus infection, while S-2P vaccination gave definite protection against SARS-CoV-2 challenge in mice. Together, our study provides direct evidence that the E484K substitution in a SARS-CoV-2 subunit protein vaccine limited the cross-reactive neutralizing antibody breadth in mice and, more importantly, draws attention to the unfavorable impact of this mutation in spike protein of SARS-CoV-2 variants on the induction of potent neutralizing antibody responses.
Keywords: SARS-CoV-2; B.1.351; E484K; subunit vaccine; neutralizing antibody SARS-CoV-2; B.1.351; E484K; subunit vaccine; neutralizing antibody

Share and Cite

MDPI and ACS Style

Hu, L.; Xu, Y.; Wu, L.; Feng, J.; Zhang, L.; Tang, Y.; Zhao, X.; Mai, R.; Chen, L.; Mei, L.; et al. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. Viruses 2022, 14, 854. https://doi.org/10.3390/v14050854

AMA Style

Hu L, Xu Y, Wu L, Feng J, Zhang L, Tang Y, Zhao X, Mai R, Chen L, Mei L, et al. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. Viruses. 2022; 14(5):854. https://doi.org/10.3390/v14050854

Chicago/Turabian Style

Hu, Longbo, Yuhua Xu, Liping Wu, Jin Feng, Lu Zhang, Yongjie Tang, Xiang Zhao, Runming Mai, Liyun Chen, Lingling Mei, and et al. 2022. "The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice" Viruses 14, no. 5: 854. https://doi.org/10.3390/v14050854

APA Style

Hu, L., Xu, Y., Wu, L., Feng, J., Zhang, L., Tang, Y., Zhao, X., Mai, R., Chen, L., Mei, L., Tan, Y., Du, Y., Zhen, Y., Su, W., & Peng, T. (2022). The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. Viruses, 14(5), 854. https://doi.org/10.3390/v14050854

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop